Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2021

Aug 4, 2021

32973_dirs_2021-08-04_1436ce43-af4a-43e1-a2cd-acd19ed8c26a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-08-03

Reporting Person: Bookman Michael (General Counsel and Secretary)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-03 Class A Common Stock P 1402 $15.00 Acquired 1402 Direct